Compared with BCMA CAR-T cells, FCRL5 CAR-T cells showed improved efficacy against MM with 1q21 gain; therefore, these patients might benefit more from FCRL5 CAR-T/IL-15 treatment, offering potential advantages to those with high-risk MM and refractory recurrence. This evidence concerns the gene FCRL5 and Miyoshi myopathy.